<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558064</url>
  </required_header>
  <id_info>
    <org_study_id>1235.13</org_study_id>
    <nct_id>NCT00558064</nct_id>
  </id_info>
  <brief_title>Filtered Trial for Amlodipine Non-responder</brief_title>
  <official_title>Filtered Trial for Amlodipine Non-responder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is
      superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately
      controlled with amlodipine 5 mg monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
    <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
    <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adequate response defined that seated trough diastolic blood pressure was &lt;90 mmHg or decreased from reference baseline by &gt;=10 mmHg at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adequate response defined that seated trough systolic blood pressure was &lt;140 mmHg or decreased from reference baseline by &gt;=20 mmHg at 8 weeks (0 percent at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Optimal, normal, high normal blood pressure were defined as follows:
Optimal: Systolic blood pressure (SBP) &lt; 120 mmHg and diastolic blood pressure (DBP) &lt; 80 mmHg
Normal: SBP &gt;= 120 mmHg or DBP &gt;= 80 mmHg and SBP &lt; 130 mmHg and DBP &lt; 85 mmHg
High normal: SBP &gt;= 130 mmHg or DBP &gt;= 85 mmHg and SBP &lt; 140 mmHg and DBP &lt; 90 mmHg
No: SBP &gt;= 140 mmHg and DPB &gt;= 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG</measure>
    <time_frame>First administration of randomised treatment to 24 hours post last dose of randomised treatment</time_frame>
    <description>Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </secondary_outcome>
  <enrollment type="Actual">531</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan+amlodipine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Essential hypertensive patients satisfying all of the following criteria;

          2. Male or Female

          3. Age &gt; 20 years

          4. Outpatient

          5. Patients who are able to stop current anti-hypertensive therapy at Visit 1 if taking
             any anti-hypertensive medications

          6. Patients with an ability to provide written informed consent in accordance with the
             related laws and guidelines such as Good Clinical Practice (GCP) and the
             Pharmaceutical Affairs Law.

        Exclusion Criteria:

          1. Taking four or more anti-hypertensive medications

          2. Secondary hypertension

          3. Mean seated diastolic blood pressure (DBP) &gt; 114 mmHg and/or mean seated systolic
             blood pressure (SBP) &gt; 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP &lt; 90 mmHg
             at Visit 3.

          4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias

          5. Congestive heart failure patients with the New York Heart Association (NYHA)
             functional class III-IV

          6. History of myocardial infarction or cardiac surgery within last 6 months

          7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI)
             within last 3 months

          8. History of unstable angina within last 3 months

          9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
             stenosis of aortic or mitral valve

         10. History of stroke or transient ischemic attack within last 6 months

         11. History of sudden exacerbation of renal function with angiotensin II receptor blockers
             (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal
             transplant or post-nephrectomy

         12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE
             inhibitors

         13. Known hypersensitivity to any component of the investigational drug , or a known
             hypersensitivity to dihydropyridine -derived drugs

         14. Hepatic and/or renal dysfunction

         15. Diagnosed biliary atresia or cholestasis

         16. Hyperkalemia

         17. Dehydration

         18. Sodium deficiency

         19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs
             (NSAIDs)

         20. Patients who cannot change to the restricted administration and dosage during study
             period

         21. Pre-menopausal women who meet any one of the following 1 - 3:

               -  Pregnant or possibly pregnant (1)

               -  Nursing (2)

               -  Desire to become pregnant during study period (3)

         22. Drug or alcohol dependency

         23. Complication of malignant tumour or a disease requiring immunosuppressants

         24. Compliance of &lt; 80% or &gt; 120% during the run-in period

         25. Receiving any investigational therapy within 3 months

         26. Judged to be inappropriate by the investigator or the sub-investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.13.037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Azumino, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashiosaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kashihara, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitaazumi-gun, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiyose, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komoro, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koshigaya, Saitama,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koto-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsudo, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mito, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimoina-gun, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjyuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjyuku-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takaoka, Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takaoka,Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.13.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsuchiura, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <results_first_submitted>November 10, 2009</results_first_submitted>
  <results_first_submitted_qc>January 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2010</results_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          <description>T40/A5 tablet, oral, once daily in the morning</description>
        </group>
        <group group_id="P2">
          <title>Amlodipine 5 mg Monotherapy</title>
          <description>A5 capsule, oral, once daily in the morning</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="264"/>
                <participants group_id="P2" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No visit within allowance period</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          <description>T40/A5 tablet, oral, once daily in the morning</description>
        </group>
        <group group_id="B2">
          <title>Amlodipine 5 mg Monotherapy</title>
          <description>A5 capsule, oral, once daily in the morning</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="269"/>
            <count group_id="B2" value="262"/>
            <count group_id="B3" value="531"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9.6"/>
                    <measurement group_id="B2" value="56" spread="9.9"/>
                    <measurement group_id="B3" value="56.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)</title>
        <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
        <time_frame>Baseline and 8 Weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)</title>
          <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="0.61"/>
                    <measurement group_id="O2" value="4.45" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.98</ci_lower_limit>
            <ci_upper_limit>6.23</ci_upper_limit>
            <estimate_desc>Difference calculated as telmisartan 40 mg plus amlodipine 5 mg fixed-dose combination minus amlodipine 5 mg monotherapy</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)</title>
        <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
        <time_frame>Baseline and 8 Weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)</title>
          <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.04" spread="0.88"/>
                    <measurement group_id="O2" value="5.77" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)</title>
        <description>Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)</title>
          <description>Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1"/>
                    <measurement group_id="O2" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)</title>
        <description>Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)</title>
          <description>Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                    <measurement group_id="O2" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
        <description>Adequate response defined that seated trough diastolic blood pressure was &lt;90 mmHg or decreased from reference baseline by &gt;=10 mmHg at 8 weeks</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
          <description>Adequate response defined that seated trough diastolic blood pressure was &lt;90 mmHg or decreased from reference baseline by &gt;=10 mmHg at 8 weeks</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5"/>
                    <measurement group_id="O2" value="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks</title>
        <description>Adequate response defined that seated trough systolic blood pressure was &lt;140 mmHg or decreased from reference baseline by &gt;=20 mmHg at 8 weeks (0 percent at baseline)</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks</title>
          <description>Adequate response defined that seated trough systolic blood pressure was &lt;140 mmHg or decreased from reference baseline by &gt;=20 mmHg at 8 weeks (0 percent at baseline)</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5"/>
                    <measurement group_id="O2" value="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
        <description>Optimal, normal, high normal blood pressure were defined as follows:
Optimal: Systolic blood pressure (SBP) &lt; 120 mmHg and diastolic blood pressure (DBP) &lt; 80 mmHg
Normal: SBP &gt;= 120 mmHg or DBP &gt;= 80 mmHg and SBP &lt; 130 mmHg and DBP &lt; 85 mmHg
High normal: SBP &gt;= 130 mmHg or DBP &gt;= 85 mmHg and SBP &lt; 140 mmHg and DBP &lt; 90 mmHg
No: SBP &gt;= 140 mmHg and DPB &gt;= 90 mmHg</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
          <description>Optimal, normal, high normal blood pressure were defined as follows:
Optimal: Systolic blood pressure (SBP) &lt; 120 mmHg and diastolic blood pressure (DBP) &lt; 80 mmHg
Normal: SBP &gt;= 120 mmHg or DBP &gt;= 80 mmHg and SBP &lt; 130 mmHg and DBP &lt; 85 mmHg
High normal: SBP &gt;= 130 mmHg or DBP &gt;= 85 mmHg and SBP &lt; 140 mmHg and DBP &lt; 90 mmHg
No: SBP &gt;= 140 mmHg and DPB &gt;= 90 mmHg</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG</title>
        <description>Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>First administration of randomised treatment to 24 hours post last dose of randomised treatment</time_frame>
        <population>Treated set: Patients randomised to the double-blind treatment period who took at least one dose either of T40+A5 or A5 during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG</title>
          <description>Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
          <population>Treated set: Patients randomised to the double-blind treatment period who took at least one dose either of T40+A5 or A5 during the double-blind treatment period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood potassium increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urine present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver function test abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration of randomised treatment to 24 hours post last dose of randomised treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          <description>T40/A5 tablet, oral, once daily in the morning</description>
        </group>
        <group group_id="E2">
          <title>Amlodipine 5 mg Monotherapy</title>
          <description>A5 capsule, oral, once daily in the morning</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="262"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

